• Interview with Victor Bulto, President, US, Novartis

  • Mar 28 2024
  • Length: 44 mins
  • Podcast

Interview with Victor Bulto, President, US, Novartis

  • Summary

  • In this important podcast episode, we interview Victor Bulto, President, US for Novartis, to discuss the company's efforts to develop groundbreaking treatments while ensuring accessibility and affordability for patients. We delve into how the pharmaceutical industry navigates numerous post-FDA approval barriers to launch new drugs and the importance of market access, patient support services, and a commitment by manufacturers to provide patient assistance and other support for patients.

    Victor Bulto, President, Novartis

    Novartis

    FDA

    Institute for Clinical and Economic Review (ICER)

    American Heart Association (AHA)

    Inflation Reduction Act (IRA)

    Pharmacy Benefit Manager (PBM)

    Medicare

    Medical terminology referenced in this episode:

    Cell therapy: CART-T

    Radioligand therapy

    RNA

    Entresto

    Molecular glues

    Targeted protein degradation

    Antisense oligonucleotides

    Small interfering RNAs: siRNAs

    LDL cholesterol

    COVID

    Hematological malignancies

    Refractory autoimmune diseases

    Questions or comments?
    Email us at comments@prescriptionforbetteraccess.com.
    Find us on social media! Follow us on X, LinkedIn, YouTube and Threads.

    Show more Show less
activate_Holiday_promo_in_buybox_DT_T2

What listeners say about Interview with Victor Bulto, President, US, Novartis

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.